Relay Therapeutics (RLAY) Revenue & Revenue Breakdown
Relay Therapeutics Revenue Highlights
Latest Revenue (Y)
$25.55M
Relay Therapeutics Revenue by Period
Relay Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $25.55M | 1749.82% |
2022-12-31 | $1.38M | -54.41% |
2021-12-31 | $3.03M | -96.34% |
2020-12-31 | $82.65M | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Relay Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | -100.00% |
2024-03-31 | $10.01M | -1000800.00% |
2023-12-31 | $-1.00K | -100.00% |
2023-09-30 | $25.20M | 21078.15% |
2023-06-30 | $119.00K | -47.35% |
2023-03-31 | $226.00K | -10.67% |
2022-12-31 | $253.00K | -26.45% |
2022-09-30 | $344.00K | -5.75% |
2022-06-30 | $365.00K | -12.89% |
2022-03-31 | $419.00K | -26.10% |
2021-12-31 | $567.00K | -14.86% |
2021-09-30 | $666.00K | -21.09% |
2021-06-30 | $844.00K | -11.34% |
2021-03-31 | $952.00K | -98.85% |
2020-12-31 | $82.65M | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | - |
Relay Therapeutics Revenue Breakdown
Relay Therapeutics Revenue Breakdown by Product
Quarterly Revenue by Product
Product/Service | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|
License | $300.00K | $300.00K | $200.00K |
Relay Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
Country | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|
License | $300.00K | $300.00K | $200.00K |
Relay Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
BPMC | Blueprint Medicines | $249.38M | $138.16M |
ARVN | Arvinas | $78.50M | $76.50M |
NRIX | Nurix Therapeutics | $76.99M | $12.09M |
FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
RLAY | Relay Therapeutics | $25.55M | - |
STOK | Stoke Therapeutics | $8.78M | $4.22M |
IPSC | Century Therapeutics | $2.23M | $771.00K |
PLRX | Pliant Therapeutics | $1.58M | - |
LIFE | aTyr Pharma | $353.00K | $235.00K |
CGEM | Cullinan Oncology | - | - |
BDTX | Black Diamond Therapeutics | - | - |
CCCC | C4 Therapeutics | - | - |
DAWN | Day One Biopharmaceuticals | - | $8.19M |
TERN | Terns Pharmaceuticals | - | - |
MLYS | Mineralys Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
EWTX | Edgewise Therapeutics | - | - |
RLAY Revenue FAQ
What is Relay Therapeutics’s yearly revenue?
Relay Therapeutics's yearly revenue for 2023 was $25.55M, representing an increase of 1749.82% compared to 2022. The company's yearly revenue for 2022 was $1.38M, representing a decrease of -54.41% compared to 2021. RLAY's yearly revenue for 2021 was $3.03M, representing a decrease of -96.34% compared to 2020.
What is Relay Therapeutics’s quarterly revenue?
Relay Therapeutics's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $10.01M, a -1000800.00% decrease from the previous quarter (Q4 2023), and a 4327.88% increase year-over-year (Q1 2023). RLAY's quarterly revenue for Q4 2023 was $-1K, a -100.00% decrease from the previous quarter (Q3 2023), and a -100.40% decrease year-over-year (Q4 2022).
What is Relay Therapeutics’s revenue growth rate?
Relay Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 743.38%, and for the last 5 years (2019-2023) was 0%.